Eli Lilly (LLY) Net Income - Minority (2009 - 2015)
Eli Lilly (LLY) reported Net Income - Minority of -$19.0 million for Q4 2015, down 27.52% on a YoY basis from -$26.2 million in Q4 2014, and down 27.52% quarter-over-quarter from -$14.9 million in Q4 2014.
Eli Lilly (LLY) Net Income - Minority (2009 - 2015) Analysis & Trends
Eli Lilly has reported Net Income - Minority for 6 years, with the latest figure at -$19.0 million in Q4 2015.
- For the quarter ending Q4 2015, Net Income - Minority fell 27.52% year-over-year to -$19.0 million; the trailing twelve-month figure through Dec 2015 stood at -$19.0 million (down 27.52% YoY), and the FY2015 full-year result was -$19.0 million, down 27.52% from the prior year.
- Net Income - Minority for Q4 2015 stood at -$19.0 million, down from -$14.9 million in the prior quarter.
- The five-year high for Net Income - Minority was $6.1 million in Q4 2011, with the low at -$19.0 million in Q4 2015.
- Historically, Net Income - Minority has averaged -$9.2 million across 5 years, with a median of -$9.3 million in 2013.
- Annual changes were most pronounced in 2012 — Net Income - Minority plunged 242.62% — and 2013, when it declined 6.9%.
- Eli Lilly's Net Income - Minority stood at $6.1 million in 2011, then sank by 242.62% to -$8.7 million in 2012, then declined by 6.9% to -$9.3 million in 2013, then plunged by 60.22% to -$14.9 million in 2014, then slipped by 27.52% to -$19.0 million in 2015.
- The last three Net Income - Minority figures came in at -$19.0 million (Q4 2015), -$14.9 million (Q4 2014), and -$9.3 million (Q4 2013), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income - Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 96,436,181.12 Bn | 96,436,176.16 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 1,017.30 Bn | 1,012.01 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 579.61 Bn | 557.55 Bn | 15.96 Bn | - |
| 4 | AbbVie | 402.30 Bn | 392.96 Bn | 10.78 Bn | - |
| 5 | Merck | 294.24 Bn | 288.59 Bn | 12.09 Bn | - |
| 6 | Amgen | 191.82 Bn | 179.78 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn | - |
| 8 | Pfizer | 149.05 Bn | 136.28 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 116.33 Bn | 105.88 Bn | 8.07 Bn | - |
| 10 | Novartis Ag | 112.59 Bn | 111.90 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2015 | -19.00 Mn |
| Dec 31, 2014 | -14.90 Mn |
| Dec 31, 2013 | -9.30 Mn |
| Dec 31, 2012 | -8.70 Mn |
| Dec 31, 2011 | 6.10 Mn |
| Sep 30, 2009 | -400,000.00 |